Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Targeted Medical Pharma, Inc. | v341824_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 18, 2013
TARGETED MEDICAL PHARMA, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-53071 | 20-5863618 |
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
2980 Beverly Glen Circle, Suite 301 Los Angeles, California |
90077 |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (310) 474-9809
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01. | Other Events. |
On April 18, 2013, Targeted Medical Pharma, Inc. issued a press release announcing that its Form S-1 registration statement, which registers up to 25,723,395 shares of common stock for resale by selling stockholders on a delayed or continuous basis, has cleared comments with the United States Securities and Exchange Commission and has requested to be declared effective on April 19, 2013. A copy of such press release is attached hereto as Exhibit 99.1.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| 99.1 | Press release of Targeted Medical Pharma, Inc., dated April 18, 2013 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 18, 2013
TARGETED MEDICAL PHARMA, INC.
By: /s/ William E. Shell
Name: William E. Shell, MD
Title: Chief Executive Officer
Exhibit Index
| 99.1 | Press release of Targeted Medical Pharma, Inc., dated April 18, 2013 |